Anixa is focused on harnessing the bodyâs immune system in the fight against cancer. Anixaâs therapeutics portfolio includes a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T, and a cancer vaccine technology focused specifically on triple negative breast cancer (TNBC), the most lethal form of the disease. Anixaâs diagnostics portfolio includes the CchekTM liquid biopsy technology, a series of inexpensive non-invasive blood tests for early detection of solid tumors based on the bodyâs immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Source
No articles found.
We are a fully integrated biopharmaceutical company focused on the development and...
We are a fully integrated biopharmaceutical com...
We are a clinical-stage biopharmaceutical company focused on developing and provid...
We are a clinical-stage biopharmaceutical compa...
OPKO Health, Inc. is a diversified healthcare company that seeks to serve unmet pa...
OPKO Health, Inc. is a diversified healthcare c...
Adverum is a clinical-stage gene therapy company targeting unmet medical need in o...
Adverum is a clinical-stage gene therapy compan...
Join the National Investor Network and get the latest information with your interests in mind.